Pandemic 2020

Status
Not open for further replies.

Fogdog

Well-Known Member
When you vaccinate try to hit everybody at once and tell the Trumpers they can use Donald's antibodies for 3 months of protection. That and NPI's should knock it down quick, periodic booster shots until something better comes along. By the time Joe starts, the scientific payoffs should be coming into use, this might help to get things under control. Antibodies, antiviral drugs, reliable rapid testing and even convalescent plasma should help a lot, along with masks and NPIs
Brilliant! No one thought of that and I'm so glad that you posted this here.

Send a note to fauci:

[email protected]
 

DIY-HP-LED

Well-Known Member
Tell Fauci to be more mindful and meditate more oh yeah and get jacked up on vitD.
He was touting vitamin D himself last week (currently recommended levels), though there is a major effort underway in the scientific community to up the recommended dose to 4000IUs, was in the news last week.
 

DIY-HP-LED

Well-Known Member
Mooo, if you don't wanna go to the slaughter house, vote. Donald is immune now, so herd immunity is on the table, front and center.
------------------------------------------------------------------------------------------------
White House Embraces Herd Immunity Despite High Death Toll Projections

Oct 14, 2020
Global healthy policy expert Dr. Vin Gupta, Morgan State University professor Jason Johnson and health policy analyst Laurie Garrett speak to the dangers of the latest plan embraced by the White House to combat the coronavirus, as trials for a vaccine and antibody treatment were halted over safety concerns.
 

DIY-HP-LED

Well-Known Member

Barron Trump tested positive for coronavirus, Melania Trump reveals
  • Barron, 14, tested positive but ‘exhibited no symptoms’
  • First lady made disclosure in statement on own experience
Melania Trump revealed on Wednesday that Barron, her 14-year-old son with the president, had at one point tested positive for the coronavirus, but has subsequently tested negative.

The first lady’s disclosure was in a statement about her own experience with the coronavirus. Donald Trump announced nearly two weeks ago that both he and the first lady had tested positive.
 

DIY-HP-LED

Well-Known Member

Novel antiviral strategy for treatment of COVID-19
A research team led by Professor Hongzhe SUN, Norman & Cecilia Yip Professor in Bioinorganic Chemistry, Department of Chemistry, Faculty of Science, and Professor Kwok Yung YUEN, Henry Fok Professor in Infectious Diseases, Department of Microbiology, Li Ka Shing Faculty of Medicine of the University of Hong Kong (HKU), has discovered a novel antiviral strategy for treatment of COVID-19.

hey discovered that a class of metallodrugs currently used in the treatment of other infectious diseases is showing efficacy to potently suppress SARS-CoV-2 replication and relieve viral-associated symptoms in an animal model.

The findings provide a new and readily available therapeutic option with high clinical potential for infection with SARS-CoV-2. This ground-breaking work has been published online in a top-class scientific journal Nature Microbiology. A related patent has been filed in the US.

SARS-CoV-2 is an emerging coronavirus that has caused over 30 million laboratory-confirmed cases and more than 1 million deaths globally of COVID-19 since December 2019. As the process of developing an effective vaccine is still ongoing, another approach for prevention and treatment of the disease is to identify anti-COVID-19 agents from existing virus-specific antiviral drugs to repurpose their uses to target the new virus. Remdesivir, a broad-spectrum antiviral drug, has been reported to show efficacy towards SARS-CoV-2. However, global shortage of the drug, its relatively high price and lack of significant clinical benefits in severe cases, are factors that have limited its wider applications. Clinical trials on a series of antiviral agents are still ongoing which have yet to demonstrate therapeutic efficacies. Therefore, greater efforts are needed to extend the evaluation to cover a wider spectrum of clinically approved drugs, which hopefully could open the way to alternative treatment strategies against the disease through some readily available channels.

Generally, metal compounds are used as anti-microbial agents; their antiviral activities have rarely been explored. After screening a series of metallodrugs and related compounds, the research team identified ranitidine bismuth citrate (RBC), a commonly used anti-ulcer drug which contains the metal Bismuth for treatment of Helicobacter pylori-associated infection, as a potent anti-SARS-CoV-2 agent, both in vitro and in vivo.

RBC targets the vital non-structural protein 13 (Nsp13), a viral helicase essential for SARS-CoV-2 to replicate, by displacing the crucial zinc(II) ions in the zinc-binding with Bismuth-ions, to potently suppress the activity of the helicase.

RBC has been demonstrated to greatly reduce viral loads by over 1,000-folds in SARS-CoV-2-infected cells. In particular, in a golden Syrian hamster model, RBC suppresses SARS-CoV-2 replications to reduce viral loads by ~100 folds in both the upper and lower respiratory tracts, and mitigates virus-associated pneumonia. RBC remarkably diminishes the level of prognostic markers and other major pro-inflammatory cytokines and chemokines in severe COVID-19 cases of infected hamsters, compared to the Remdesivir-treated group and control group.

RBC exhibits a low cytotoxicity with a high selectivity index at 975 (the larger the number the safer the drug), as compared to Remdesivir which has a low selectivity index at 129. The finding indicates a wide window between the drug's cytotoxicity and antiviral activity, which allows a great flexibility in adjusting its dosages for treatment.

The team investigated the mechanisms of RBC on SARS-CoV-2 and revealed for the first time the vital Nsp13 helicase as a druggable target by RBC. It irreversibly kicks out the crucial zinc(II) ions in the zinc-binding domain to change it to bismuth-bound via a distinct metal displacement route. RBC and its Bi(III) compounds dysfuntionalised the Nsp13 helicase and potently inhibited both the ATPase (IC50=0.69 μM) and DNA-unwinding (IC50=0.70 μM) activities of this enzyme.

The research findings highlight viral helicases as a druggable target, and the high clinical potential of bismuth(III) drugs and other metallodrugs for treatment of SARS-CoV-2 infections. Hopefully, following this important breakthrough, more antiviral agents from readily available clinically approved drugs could be identified for potential treatment of COVID-19 infections. They can be in the form of combination regimens (cocktails) with drugs that exhibit anti-SARS-CoV-2 activities including RBC, dexamethasone and interferon-β1b.
 

DIY-HP-LED

Well-Known Member

Big global study finds remdesivir doesn't help Covid-19 patients

(CNN)In a study it described as both conclusive and disappointing, the World Health Organization said the antiviral drug remdesivir has "little or no effect on mortality" for patients hospitalized with coronavirus and it doesn't seem to help patients recover any faster, either.

Until now, remdesivir has been the only drug that appeared to have specific effects for coronavirus. It was the only drug with an Emergency Use Authorization for Covid-19 from the US Food and Drug Administration.
Results of the WHO study have not been published in a peer-reviewed medical journal. But WHO posted them to a pre-print server.

The WHO study reviewed remdesivir and three other repurposed drugs: hydroxychloroquine, the HIV combination of lopinavir and ritonavir and interferon. None of them helped patients live any longer or get out of the hospital any sooner, WHO said.

The trial was able to generate conclusive evidence on the impact the drugs had on mortality, the need for ventilation, and duration of hospital stay.

"For each drug in the study, the effect on mortality was disappointingly unpromising," WHO said in a statement.
Several other studies had found that hydroxychloroquine, an anti-malarial drug, was of no benefit to coronavirus patients, as had several studies looking at the HIV drug combination.

The study covered more than 11,000 coronavirus patients in 30 countries. "The protocol was designed to involve hundreds of potentially over-stressed hospitals in dozens of countries," the international team of researchers wrote. They said they have submitted their findings to a medical journal.

Prior to the WHO study, a large controlled study of remdesivir in the US found that it shortens recovery time by about a third in severely ill, hospitalized adults with Covid-19, but does little to help those with milder cases.
Gilead Sciences, the drug's maker, said the findings did not mean the drug, sold under the brand name Veklury, is of no benefit.

"The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury (remdesivir). We are concerned that the data from this open- label global trial have not undergone the rigorous review required to allow for constructive scientific discussion," Gilead said in a statement.

"The benefits of Veklury have been demonstrated in three randomized, controlled clinical trials, including a randomized, double-blind, placebo-controlled clinical trial -- the gold standard for evaluating the efficacy and safety of investigational drugs."

The WHO-led researchers say their trial, called the Solidarity trial, will continue. "Newer antiviral drugs, immunomodulators and anti-SARS COV-2 monoclonal antibodies are now being considered for evaluation via the Solidarity Therapeutics trial," WHO said.

Monoclonal antibody treatments include Regeneron's dual antibody cocktail and Eli Lilly and Co's double antibody therapy.
 

schuylaar

Well-Known Member
COVID-19 affects men more than women; type A blood the most; type O the least.

the answer is in our blood..type O is resistant to Coronavirus ie common cold in general.

:mrgreen:
 

schuylaar

Well-Known Member
Pro Life Republicans have no problem with killing older people or healthcare workers for trump.
whatever happened to separation of Church and State? i don't get it- don't want an abortion because of YOUR religious views? don't have one.

why are they making this decision for me; for all americans?

christ until coney barrett, i didn't realize there is stare decisis on contraception being legal for a married couple- who's business is it of theirs? is it really necessary? crazy to think that is had to be made a law.

if religious institutions wish to keep their kushy non-profit status then they cannot be involved in making law, yet they are; they do have it both ways in this country.

all hail corporate america and their non-profits.
 

DIY-HP-LED

Well-Known Member
Trump holds indoor rally for hundreds of seniors

Donald Trump rallies support from seniors in Florida, saying they’ll be first in line for a vaccine and suggests “the light at the end of the tunnel is near” on the COVID-19 pandemic.
 
Status
Not open for further replies.
Top